Eli Lilly and Company today announced changes in its executive committee.
Johna Norton will be promoted to senior vice president of global quality April 1, replacing Fionnuala Walsh, who is retiring April 15 after 28 years at Lilly. Norton currently is vice president, Global Quality for API Manufacturing, Product Research and Development.
Bart Peterson, senior vice president of Corporate Affairs and Communications, will leave Lilly March 31 to pursue personal business interests and expand his community volunteer commitments. Peterson, a former two-term mayor of Indianapolis, joined Lilly in 2009. A search currently is under way for his replacement.
“Fionnuala and Bart have been invaluable members of our executive committee as our business has gone through tremendous transformation during the last few years,” said David Ricks, Lilly president and CEO. “Fionnuala has worked diligently to ensure that we have maintained the highest quality standards across our worldwide operations, which is absolutely essential to our business. And, Bart’s leadership and political acumen have been vital to help us meet the significant challenges of an incredibly complex health care environment. His strong passion and vision for global health has been instrumental in making life better for people around the world.”
Ricks said Lilly is very fortunate to have Norton to step into Walsh’s role. “Johna lives Lilly’s values every day, has a strong commitment to our mission, sets the highest standards for her work and has demonstrated leadership in partnering across the business. She has a deep knowledge of our manufacturing and quality systems and has worked effectively with regulators globally.”
Source: Eli Lilly and Company
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.
